Injectable Ampoules and Parenteral Formats
Last updated:
Injection is the reference route for peptides and proteins because it bypasses every absorption barrier. It also makes the product a drug in every market, requiring sterile manufacture, marketing authorization and prescriber control. Vegalab's role here is formulation development with licensed partners, focused on release profile and stability.
Why peptides are injected
Subcutaneous injection delivers near-complete bioavailability for most peptides, avoiding gut enzymes and epithelial barriers. The remaining problem is half-life: many native peptides clear in minutes. Approved solutions include fatty acid acylation for albumin binding (semaglutide, weekly), PEGylation, Fc fusion, and biodegradable PLGA microsphere depots (leuprolide, exenatide extended release) that release over weeks to months. Each approach trades manufacturing complexity for fewer injections, and each required a full drug development program to reach approval.
Manufacturing and regulatory requirements
Sterile injectables must be made under EU GMP Annex 1 (revised 2022) or equivalent current GMP, with validated aseptic processing or terminal sterilization, particulate and endotoxin limits, and container closure integrity. Every injectable product requires a marketing authorization or, for investigational use, a clinical trial authorization. Vegalab works inside these licensed systems. Stability, sterility and release data must support every lot released for clinical or commercial use.
Ampoules outside the injectable category
Vegalab Professional Ampoules are topical or drinkable formats, not injectables. The word ampoule describes the sealed single-dose container. This page covers only parenteral drug development for licensed sponsors, where Vegalab contributes formulation design and release-profile work, and the sponsor holds manufacturing and regulatory responsibility. Any consumer-facing content about injecting peptides is out of scope for this site. Formulation work here is scoped by the sponsor's development plan and regulatory strategy.
Key facts
- Revised EU GMP Annex 1 on the manufacture of sterile medicinal products came into effect in August 2023 (European Commission, EudraLex Vol 4 Annex 1, 2022)
- Exenatide extended-release uses PLGA microspheres for once-weekly dosing (FDA label, Bydureon 2012)
- Semaglutide's C-18 fatty diacid side chain enables albumin binding and a half-life of about one week (FDA label, Ozempic 2017)
- Forzinity (elamipretide) is an FDA-approved injectable peptide for Barth syndrome (FDA label, Forzinity 2025)
How our delivery technology applies
For injectables, a biodegradable multi-layer shell is a release-rate device: layer number and thickness set how fast a peptide is released from a subcutaneous depot, and inner layers can protect a payload during storage. This is comparable in principle to PLGA microspheres. Any such program runs with a licensed sponsor under GMP, with sterile process validation at the sponsor's aseptic facility.
Licensed sponsors: discuss a controlled-release parenteral program with Vegalab.